Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Debt / NOTE 0.750% 5/1
-
Number of holders
-
43
-
Total 13F principal, excl. options
-
323,098,546
-
Principal change
-
-15,105,191
-
Total reported value, excl. options
-
$319,930,461
-
Value change
-
-$15,166,559
-
Number of buys
-
13
-
Number of sells
-
-24
-
Price
-
$0.9885
Significant Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 as of Q2 2021
53 filings reported holding 53220KAF5 - LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 as of Q2 2021.
LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 has 43 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $323,098,546 of principal
.
Largest 10 bondholders include WOLVERINE ASSET MANAGEMENT LLC ($42,343,000 of principal), CANYON CAPITAL ADVISORS LLC ($40,000,000 of principal), LAZARD ASSET MANAGEMENT LLC ($36,500,000 of principal), AVIVA PLC ($31,500,000 of principal), Polygon Management Ltd. ($21,600,000 of principal), D. E. Shaw & Co., Inc. ($18,540,000 of principal), OAKTREE CAPITAL MANAGEMENT LP ($18,449,999 of principal), ADVENT CAPITAL MANAGEMENT /DE/ ($15,000,000 of principal), STATE STREET CORP ($14,672,000 of principal), and Davidson Kempner Capital Management LP ($12,500,000 of principal).
This table shows the top 43 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.